Developing drugs for the treatment of


About Us

Haoma Medica is a UK based biotech company that focuses on treatments for Osteoporosis and Osteopenia as well as blood clotting management. The Osteoporosis & Osteopenia drug referred to as NaQuinate and commercially as Osteopura, is a novel class of compound that has a new mechanism of action compared with existing treatments and is designed for low dose oral administration. The chemical compound, NaQuinate, occurs naturally within the body and appears to preserve both bone mass and bone architecture and thus the safety profile of this therapeutic approach has significant potential for the long-term treatment of the serious condition of Osteoporosis.


The active substance in Osteopura is present in all people, but only in very small amounts. Osteopura boosts the levels of this naturally occurring compound to preserve bone integrity. Haoma Medica started with the platform of “working with nature and not against it”.   


A novel therapeutic for the treatment of Osteoporosis

Anticipated Strengths of NaQuinate

  • Novel class of compound

  • Unique mechanism of action

  • Product naturally occuring in the body

  • Small molecule

  • Low toxicity

  • Low dosage

  • Ability to improve bone quality not just quantity

  • Non gender specific 

  • Administered orally

  • ‘Quick On, Quick Off'

  • Inexpensive to manufacture

  • Beneficial additional effects

Inhibits bone loss in a pharmaceutical industry “Gold Standard” animal model of postmenopausal osteoporosis. The market is ready for a novel treatment with a new mechanism of action in the management of patients at risk of fracture; one that addresses the unmet need for a therapy with better efficacy in the treatment and prevention of long bone fractures, and one that provides anabolic characteristics but with a better safety profile. We believe NaQuinate and Osteopura can meet these requirements.


Patent Update

Haoma Medica has three patents, two have been granted and one is pending grant. They cover the following countries: UK, US, Canada, Australia, Japan, Korea, Hong Kong, Russia, India, China, Brazil, Isreal and the European zone


Our current strategy within the early clinical development phase is focused on identifying and understanding more about NaQuinate’s unique mechanism of action compared with all current treatments and its ability to improve bone quality not just quantity.

Phase I

We have initiated our first in human study. This is a single and multiple ascending dose study to evaluate the safety, tolerability and pharmacokinetics of varying doses of NaQuinate in healthy subjects. The study is currently ongoing.

Phase Ib

Phase Ib Study in Healthy Post-Menopausal Women has been initiated. It is designed as a randomised, double-blind, placebo-controlled parallel group study to investigate the safety, tolerability, pharmacokinetic and pharmacodynamic effects of NaQ in healthy post-menopausal women with low bone mineral density. The objective is to study the safety and tolerability of NaQ with longer term treatment (28 days) in our target subject demographic prior to a 2-year treatment patient study in post-menopausal women with osteoporosis. In addition, the study will help to confirm a bone pharmacodynamic effect in humans.

Phase II

Our proposed Phase II study combines the objectives of a Phase IIa proof of concept study in patients with osteoporosis and osteopenia and a Phase IIb dose ranging study to help select doses for Phase III pivotal registration trials. More advanced technologies such as quantitative computed tomography (QCT) and High Resolution peripheral QCT will be used to evaluate the effects of treatment on different bone compartments and at a level that can evaluate drug treatment effects on bone geometry and microarchitecture (for e.g. cortical thickness and cortical porosity). Estimates of bone strength in patients will also be assessed using finite element analysis. We expect to initiate the Phase II program for Osteoporosis later in 2020.


World Osteoporosis Day

WOD marked on October 20 each year, is a year-long campaign dedicated to raising global awareness of the prevention, diagnosis and treatment of osteoporosis and related bone diseases. It aims to put osteoporosis and fracture prevention on the global health agenda and reaches out to health-care professionals, the media, policy makers and the public at large. The World Osteoporosis Day campaign calls on the general public to take early action to protect their bone and muscle health, in order to enjoy a good quality of life and independence in the future. 

Fund Raising

Series A Raise

Haoma Medica will look to raise a Series A funding round in Q1, 2021. This will provide funding for additional Pre-Clinical research and begin Phase II trials.

Please contact us should you be interested in investing in Haoma Medica's Series A raise. We would be prepared to discuss details of the raise as early as September, 2020.

Contact Information

Office Phone  (+44) 0207 629 1954

LBIC Phone    (+44) 0189 526 5540

Emails (CSO) (CEO) (CFO) (CMO)

Mailing Address

Haoma Medica Ltd.

c/o London BioScience Innovation Centre

2 Royal College Street 

London, England

United Kingdom


LinkedIn Haoma Medica

Company Registration GB No. 06784000